ECM
PBYI icon

Endurant Capital Management’s Puma Biotechnology PBYI Stock Holding History

Endurant Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,081
Closed -$1.15M – 70
2018
Q3 		$1.15M Sell
25,081
-15,707
-39% -$757K 0.51% 43
2018
Q2 		$2.41M Buy
40,788
+16,088
+65% +$932K 1.05% 26
2018
Q1 		$1.68M Sell
24,700
-5,200
-17% -$389K 0.63% 40
2017
Q4 		$2.96M Buy
29,900
+8,500
+40% +$951K 0.9% 41
2017
Q3 		$2.56M Buy
21,400
+2,100
+11% +$195K 0.78% 47
2017
Q2 		$1.69M Sell
19,300
-10,300
-35% -$576K 0.48% 53
2017
Q1 		$1.1M Buy
+29,600
New +$1.08M 0.35% 64
2015
Q3 		– Sell
-3,700
Closed -$432K – 89
2015
Q2 		$432K Buy
3,700
+1,400
+61% +$254K 0.13% 89
2015
Q1 		$543K Sell
2,300
-600
-21% -$128K 0.18% 82
2014
Q4 		$549K Buy
+2,900
New +$643K 0.22% 79

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Endurant Capital Management's PBYI Position: Q4 2018 in Review

Endurant Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 25,081 shares — an estimated $1.15M sold.

Endurant Capital Management first reported a position in PBYI in Q4 2014 and held it in 10 quarters. The position peaked at $2.96M in Q4 2017. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Endurant Capital Management reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Endurant Capital Management sold 25,081 Puma Biotechnology shares in Q4 2018, an estimated $1.15M.
  • Endurant Capital Management first reported a position in Puma Biotechnology in Q4 2014 and held it in 10 quarters.
  • Endurant Capital Management's Puma Biotechnology position peaked at $2.96M in Q4 2017.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Endurant Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.